Yissum - Research Development Company of the Hebrew University

Precise Epigenome Therapy Using DNA Methylation and Demethylation Enzymes Fused to CRISPRdCas9

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

Platform patent allows modifications of the DNA
Project ID : 6-2016-4301

Description of the technology

Category

Medical Sciences

Highlights

Epigenome editing by DNA methylation or demethylation of regulatory sequences are widely required in medicine and in biomedical research, but current technologies are non-specific and provide unpredictable effects. This technology allows one to modify DNA methylation level at specific genomic sites.

Our Innovation

Targeted DNA demethylation and activation of endogenous genes was demonstrated using TALE-TET1 fusion proteins, but its applicability is restricted by inherent limitations of the TALE genome editing technology.The CRISPR/Cas9 technology recently became the method of choice for genomic editing, having numerous applications in genomic research and is highly demanded in the gene therapy field. This technology combines the proved capability of TET fusion proteins to alter the DNA methylation level and modify the expression level of genes without changing the DNA sequence, with the established flexibility and versatility of the CRISPR/Cas9 genome editing assay.

Advantages

  • Tools for epigenome editing, particularly demethylation of desired genomic targets, are highly demanded among biomed companies in the field of developing epigenetic anti-cancer therapy protocols.

The Opportunity

New methylome editing assays may be used in a broad spectrum of biomed research and therapeutic applications including, but not limited to:

  • Modification and tuning of gene activity level,
  • Uncover and tune of cancer regulatory networks,
  • Mapping and targeting driving regulatory epimutations and,
  • Exposure of cancer cells to the immune system.

Current Development Stage

TRL3 Experimental proof of concept

Following targeted demethylation of particular sites within KCNE4 and HBB gene regions, methylation levels of the targeted sites were significantly reduced. Based on these results of the inventors are aiming (in the second part of their study) to provide exact examples for the application of the targeted demethylation assay in tuning the regulatory networks of cancer genes.

Project manager

Shani Bullock
VP, Business Development, Healthcare

Project researchers

Asaf Hellman
HUJI, School of Medicine - IMRIC
Developmental Biology and Cancer Research

Nurit Meron
HUJI, School of Medicine - IMRIC

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Diagnostic
  • Therapeutic
  • Other Medical/Health Related
  • Agro and Marine biotech
  • Anatomy, Pathology, Immunology, Physiology
  • Clinical Medicine
  • Life Science & Biotechnology
  • Oncology / Cancer

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.